Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2014 07:00 ET | Source: Raptor Pharmaceutical Inc

Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial

18 Month Clinical Results Showed Significantly Slower Progression of Total Motor Score in RP103 Treated Patients Without Tetrabenazine Conference Call and Webcast Today at 8:30 a.m. EST NOVATO,...